NEWS

Tests Demonstrate Ability to Stratify Patients Treated with Immunotherapy

“VeriStrat appears to be a robust assay and should be used for EGFR wild-type patients with squamous cell lung cancer,” says study author Glenwood D. Goss, MD, professor of medicine and an oncologist in the division of medical oncology at the University of Ottawa. Biodesix presented data relating to immunotherapy selection, afatinib efficacy.

Biodesix: 216 of the Inc500 for 2015

“Biodesix discovers and commercializes cancer tests that help patients and their doctors make more informed decisions about treatment based on a patient’s unique molecular profile….” Read more at inc.com For Customer Support, call: (866)...

Study: better NSCLC outcomes with proteomic test

The VeriStrat proteomic test, when used to help guide treatment of patients with advanced non-small cell lung cancer, improves overall survival and decreases medical costs in the U.S. payer system, said a study published recently in the journal Lung Cancer. “Systems...

United Healthcare Approves Coverage for Biodesix’ VeriStrat Test

Biodesix, Inc. today announced that its VeriStrat® test received a positive coverage decision from United Healthcare (NYSE: UNH), one of the largest commercial insurance company in the US, with a published 44.7 million covered lives. In its Medical Policy...